The method of embodiment 158, wherein a concentration of the anti-apoptotic agent is 0.001 M, 0.005 M, 0.01 M, 0.05 M, 0.10 M, 0.5 M, 1 M, 5 M, 10 M, 20 M, 30 M, 40 M, 50 M, 60 M, 70 M, 80 M, 90 M, 100 M, 120 M, 140 M, 160 M, 180 M, or 200 M
Longacting GHRH analogues such as CJC1295 and shortacting GHRPs (Ipamorelin, Sermorelin) are best injected 3060 min before sleep to boost nocturnal growthhormone pulsatility, deepening slowwave sleep
Range tested: Trials have investigated doses from 0.3 mg up to 6.0 mg weekly, with 2.44.8 mg showing the most consistent weight-loss results
The data on DSIP come from basic research they do not confirm efficacy or safety in humans
Kingdom providers review medical history, risk factors, and goals before initiating treatment and continue monitoring throughout care